Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phexxi is an FDA-approved, non-hormonal, on-demand vaginal contraceptive gel developed by Evofem Biosciences. It functions as a vaginal pH modulator, maintaining the acidic environment of the vagina (pH 3.5 to 4.5) even in the presence of alkaline semen, which typically raises vaginal pH to levels conducive to sperm motility. By maintaining acidity, Phexxi inhibits sperm from swimming, thereby preventing fertilization. It is applied via a pre-filled applicator within one hour before vaginal intercourse. The product is also being investigated under the development code GEN-1 (formerly EVO100) for the prevention of certain sexually transmitted infections, including chlamydia and gonorrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phexxi.